TrialCardiovascular diabetology2023

Effects of dapagliflozin and dapagliflozin-saxagliptin on erythropoiesis, iron and inflammation markers in patients with type 2 diabetes and chronic kidney disease: data from the DELIGHT trial.

Akihiko Koshino et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.